Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions.

Some cross-sectional epidemiological studies have reported positive associations of serum concentrations of non-high density lipoprotein cholesterol with serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA). However, the strength of the reported associations is inconsistent for exposure-response across three orders of magnitude of serum PFOS and/or PFOA concentrations. These positive associations are unexpected based on toxicological/mechanistic studies, suggesting that the associations may have a biological, rather than a causal, basis. This study tested the hypothesis that PFOS and PFOA distribute into serum lipoprotein fractions such that increases in serum lipoproteins would result in corresponding increases in serum concentrations of PFOS and PFOA. Based on observed binding of PFOS and PFOA to isolated β-lipoproteins in physiological saline (96% and 40% bound, respectively) in preliminary experiments using ultrafiltration and LC-MS/MS methods, binding to human donor plasma lipoprotein fractions was investigated by two density gradient methods. The majority of PFOS and PFOA recovered masses were found in lipoprotein-depleted plasma. Plasma density gradient fractionation data suggested that maximally 9% of PFOS distributes to lipoprotein-containing fractions, yet only 1% or less of PFOA is so distributed. These data do not support a strong role for plasma lipoprotein fractions in explaining the inconsistent dose-response associations reported in cross-sectional epidemiological studies.

[1]  Geary W Olsen,et al.  Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers , 2007, International archives of occupational and environmental health.

[2]  M. V. van Erk,et al.  Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  C. Elcombe,et al.  Hepatocellular hypertrophy and cell proliferation in Sprague–Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR , 2010, Archives of Toxicology.

[4]  C. E. West,et al.  Separation of plasma lipoproteins by density-gradient ultracentrifugation. , 1975, Analytical biochemistry.

[5]  O. Spydevold,et al.  The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. , 1992, Biochimica et biophysica acta.

[6]  C. Elcombe,et al.  Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. , 2003, Toxicology.

[7]  D. Bissett,et al.  A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Olsen,et al.  Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats. , 2012, Toxicology.

[9]  John W Green,et al.  Cross-Sectional Study of Lipids and Liver Enzymes Related to a Serum Biomarker of Exposure (ammonium perfluorooctanoate or APFO) as Part of a General Health Survey in a Cohort of Occupationally Exposed Workers , 2007, Journal of occupational and environmental medicine.

[10]  C. Elcombe,et al.  Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR. , 2012, Toxicology.

[11]  Gerald L Kennedy,et al.  Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). , 2006, Toxicology.

[12]  P. Hinderliter,et al.  Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  G. W. Jepson,et al.  Binding of perfluorooctanoic acid to rat and human plasma proteins. , 2003, Chemical research in toxicology.

[14]  Kyle Steenland,et al.  Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. , 2009, American journal of epidemiology.

[15]  C. Elcombe,et al.  Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  A. Bergman,et al.  A temporal trend study (1972-2008) of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm, Sweden. , 2011, Environment international.

[17]  S. Tittlemier,et al.  Altered Fatty Acid Homeostasis and Related Toxicologic Sequelae in Rats Exposed to Dietary Potassium Perfluorooctanesulfonate (PFOS) , 2008, Journal of toxicology and environmental health. Part A.

[18]  C. Cavallotti,et al.  Determination of energies and sites of binding of PFOA and PFOS to human serum albumin. , 2010, The journal of physical chemistry. B.

[19]  Mark R Cullen,et al.  Longitudinal Study of Serum Lipids and Liver Enzymes in Workers With Occupational Exposure to Ammonium Perfluorooctanoate , 2007, Journal of occupational and environmental medicine.

[20]  J. Mandel,et al.  PLASMA CHOLECYSTOKININ AND HEPATIC ENZYMES, CHOLESTEROL AND LIPOPROTEINS IN AMMONIUM PERFLUOROOCTANOATE PRODUCTION WORKERS , 2000, Drug and chemical toxicology.

[21]  Geary W Olsen,et al.  Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. , 2007, Environmental research.

[22]  D. Consonni,et al.  Thirty Years of Medical Surveillance in Perfluooctanoic Acid Production Workers , 2009, Journal of occupational and environmental medicine.

[23]  I. Godsland,et al.  Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis This research was supported by a grant from GlaxoSmithKline. Published, JLR Papers in Press, March 12, 2008. , 2008, Journal of Lipid Research.

[24]  D. Savitz,et al.  Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. , 2010, Archives of pediatrics & adolescent medicine.

[25]  J. Dietschy,et al.  Role of liver in the synthesis of cholesterol and the clearance of low density lipoproteins in the cynomolgus monkey. , 1995, Journal of lipid research.

[26]  T. Webster,et al.  Exposure to Polyfluoroalkyl Chemicals and Cholesterol, Body Weight, and Insulin Resistance in the General U.S. Population , 2009, Environmental health perspectives.

[27]  Jeffrey H Mandel,et al.  Epidemiologic Assessment of Worker Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations and Medical Surveillance Examinations , 2003, Journal of occupational and environmental medicine.

[28]  G. Olsen,et al.  Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.